An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients

Overview of attention for article published in Immunity & Ageing, November 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 2 X users

patent: 1 patent

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 66 Mendeley

Summary X Patents Dimensions citations

So far, Dimensions has found 20 publications that cite this research output.

20

The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.

Elderly and COVID-19

Book chapter (November 2023)

REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT

Article in Expert Opinion on Biological Therapy (April 2023)

An overview on the treatments and prevention against COVID-19

Article in Virology Journal (February 2023)